Market capitalization is the total value the stock market puts on a company: its share price multiplied by the number of shares outstanding. Each point here is the share count reported in a filing multiplied by the closing price on that filing date, adjusted for later stock splits, so the history moves when a new filing arrives rather than with each day's trading. A larger market cap means investors collectively value the company more highly; by itself it says nothing about profit or debt. Annual points keep the latest observation in each calendar year.
Grace Therapeutics, Inc. market cap for the quarter ending 2026-08-11 was $44.18M, a 2.39% increase year-over-year.
Grace Therapeutics, Inc. market cap for the quarter ending 2026-06-30 was $37.02M, a 10.16% decline year-over-year.
Grace Therapeutics, Inc. market cap for the quarter ending 2026-06-15 was $36.29M, a 14.24% decline year-over-year.
Grace Therapeutics, Inc. market cap for the quarter ending 2026-03-31 was $74.83M, a 139.25% increase year-over-year.
Grace Therapeutics, Inc. market cap for fiscal 2026 was $44.18M.
Grace Therapeutics, Inc. market cap for fiscal 2025 was $53.54M, a 41.18% increase from fiscal 2024.
Grace Therapeutics, Inc. market cap for fiscal 2024 was $37.92M.
Grace Therapeutics, Inc. market cap for fiscal 2023 was $21.34M, a 84.67% decline from fiscal 2022.